Safety and efficacy of Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles as First line Therapy in Advanced colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2616805
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Alternating mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab every 4cycles.
Primary outcome(s): PFS
Study Design: Single arm Non-randomized
创建时间：
2008-03-15
